Quantcast

Latest Antiandrogens Stories

2008-10-17 09:00:06

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the Prostate Cancer Foundation Scientific Retreat. The Prostate Cancer Foundation Scientific Retreat is currently taking place in Lake Tahoe, Nevada. The clinical trial of CB7630 was conducted at the University of Texas M.D. Anderson Cancer Center in order to investigate associations between...

2008-10-14 00:00:41

By Marie Price A new law requiring women to undergo an ultrasound before getting an abortion has been challenged in a lawsuit filed in Oklahoma County District Court by the Center for Reproductive Rights on behalf of Nova Health Systems, which does business as Reproductive Services in Tulsa. The new law also requires physicians to describe what an ultrasound shows. In their petition, center attorneys say the law imposes burdensome restrictions on performance of abortions, subjects...

2008-09-24 09:00:49

US-based healthcare company AstraZeneca has announced that the FDA has granted an additional six-month period of exclusivity to market Casodex for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of Casodex in a pediatric setting but will not be seeking an indication in this population. Casodex is currently approved in the US at a dose of 50mg daily tablet for use in...

2008-09-23 18:00:13

Men with locally advanced prostate cancer will survive substantially longer when radiation is added to their treatment plan, Swedish researchers said. Lead author Dr. Anders Widmark of Umea University in Sweden said for men with locally advanced prostate cancer the addition of radiation treatment to anti-androgen hormone therapy reduces the risk of dying of prostate cancer by 50 percent compared to those who have anti-androgen hormone treatment alone. Locally advanced prostate cancer is...

2008-09-22 15:00:14

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population....

2008-08-22 15:00:17

Some drugs given to men to help treat prostate cancer may actually spur some cancer cells to grow, U.S. researchers said. The study, published online in two papers in the Proceedings of the National Academy of Sciences, said hormone therapy, a common treatment for men with advanced prostate cancer, generally keeps the cancer at bay for a year or two. But then, for reasons scientists have never understood, the treatment fails in patients whose disease has spread. Chawnshang Chang,...

2008-07-28 18:00:17

SCIENTISTS are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years. Abiraterone could treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they said. The drug works by blocking the hormones which fuel the cancer. The Institute of Cancer Research hopes a simple pill form will be available in two to three years. An advanced clinical trial involving 1,200...

2008-07-28 09:00:31

Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePak(TM) for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term. The two products in Xolegel CorePak are new Xebcort(TM) Gel, a 1% hydrocortisone gel, and Xolegel(R) (ketoconazole, USP) Gel, 2%. Xebcort Gel provides quick symptom relief and is presented as a 0.8...

2008-07-24 00:00:18

By Phil Skelton Health reporter Prostate cancer patients in Gloucestershire have welcomed news of a new drug to treat an aggressive form of the disease. Abiraterone has been developed to fight prostate cancer, which kills 9,000 men in England and Wales every year, according to the NHS. Preliminary trials have shown that the drug can reverse even the most aggressive cancers in up to 80 per cent of cases. It works by blocking the hormones which fuel the cancer. The Institute of Cancer...

2008-07-22 21:00:17

The Phase 1 clinical trial of the drug abiraterone revealed significant tumor shrinkage in men with advanced prostate cancer, researchers in Britain said. The trial also found dramatic falls in the prostate specific antigen levels in the majority of advanced prostate cancer patients who received the drug. The clinical trial was undertaken by London-based The Institute of Cancer Research and The Royal Marsden Hospital. Lead researcher Dr. Johann de Bono said the the new drug...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related